时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
研究问题
However, the impact of sarcopenia on the tolerability and prognosis of patients with ILD who initiate nintedanib treatment remains unknown.In the present study, we aimed to examine whether baseline sarcopenia affects the safety and tolerability and the outcomes of patients with ILD receiving nintedanib.MethodsStudy design, patient enrollment, and ethicsThis was a single-institution, retrospective study.
方法
A growing number of patients with ILD are being treated with antifibrotic agents, such as nintedanib and pirfenidone.；However, the impact of sarcopenia on the tolerability and prognosis of patients with ILD who initiate nintedanib treatment remains unknown.In the present study, we aimed to examine whether baseline sarcopenia affects the safety and tolerability and the outcomes of patients with ILD receiving nintedanib.MethodsStudy design, patient enrollment, and ethicsThis was a single-institution, retrospective study.；We included the consecutive patients with ILDs who were prescribed nintedanib between 2015 and 2023 at Hirosaki University Hospital.
核心结论
These findings suggest that nintedanib may not be well tolerated in patients with sarcopenia, rather than indicating that nintedanib is less effective in patients with sarcopenia.；Therefore, we cannot confidently conclude that nintedanib does not exert its effect in patients with sarcopenia.Sarcopenia was first described by the EWGSOP in 2010 [12].；The poor outcomes in the sarcopenia group may not be attributable to the IPF pathology, which is often associated with a higher incidence of exacerbation.Our study also demonstrated that dose reduction or discontinuation of nintedanib was more frequent in the sarcopenic group.
局限
However, the impact of sarcopenia on the tolerability and prognosis of patients with ILD who initiate nintedanib treatment remains unknown.In the present study, we aimed to examine whether baseline sarcopenia affects the safety and tolerability and the outcomes of patients with ILD receiving nintedanib.MethodsStudy design, patient enrollment, and ethicsThis was a single-institution, retrospective study.；Sarcopenia estimated from skeletal muscle using CT images may also be noted.Our study has some limitations.
对本项目的价值
中等价值：属「衰弱 / 肌少症功能结局」方向；肌肉骨骼 / 衰弱 / 肌少症栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.6/5（★★★☆☆）
全文来源
PubMed PMC JATS（正文 25,579 字符，题名指纹 1.0，已过 PubMed PMCID 官方关联 + 题名指纹 + 正文长度归属校验）
原文题录
- 中文题名：肌少症影响间质性肺病患者尼达尼布治疗的结局与耐受性：回顾性研究
- 英文标题：Sarcopenia affects the outcomes and tolerability in patients with interstitial lung disease receiving nintedanib: a retrospective study.
- 期刊与标识：BMC pulmonary medicine · PMID 42972370 · DOI 10.1186/s12890-026-04564-w · PMC PMC13726055